Jill Feldman: We must try to be ‘precise’ with dosing so people can LIVE better
Jill Feldman shared on X/Twitter:
“Thank you, Associated Press for this story on dosing!
No one should have to endure the avoidable harmful effects of research drugs.
We are in the era of precision medicine, so if we know most new research drugs DON’T cure people, we must try to be ‘precise’ with dosing so people can LIVE better!”
View the article.
Source: Jill Feldman/X
Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023